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Abstract The aim of the work was to evaluate the in vivo
biological behaviour of polymeric membrane materials
for glaucoma implants. The base material was biostable
synthetic terpolymer (PTFE–PVDF–PP) with proved bio-
compability (PN-EN ISO 10993). The samples manufac-
tured in the form a membrane were subjected to chemical
and physical treatment to create an open pore system
within the polymer matrix. As a porogenic phase biode-
gradable natrium alginate in a ﬁbrous form was employed.
The non-perforating deep sclerectomy technique was per-
formed in a rabbit model. The clinical observations were
made after 14 and 30 days. During the study clinical
symptoms of a moderate degree were observed, and his-
topathological changes were typical for foreign body
implantation. At the end stage of the study no signiﬁcant
difference in histopathological assessment was found
between control and experimental group. Similarities
observed in both groups and relatively mild histopatholo-
gical changes in the tissue surrounding the implant indicate
that the observed symptoms come from a deep scleral
trauma caused by surgery, and not by the presence of the
implant itself.
1 Introduction
According to WHO data, in 2002 about 37 million people
are blind worldwide. Glaucoma is one of the leading causes
of blindness (12.3%, 4.4 million). At present 7 million
people is blind because of glaucoma. It is assumed that in
2010 the number of blind people will increase to 8.4 mil-
lion and in 2020 to over 11 million. At the same time, the
number of patient suffering from glaucoma will increase to
60.5 million in 2010 and over 80 million in 2020 [1].
Standard procedures in glaucoma therapy are conservative
(pharmacological) treatment, laser therapy and surgical
treatment [2, 3]. Surgery used as a therapy after other
treatment strategies, such as medications and laser surgery,
have failed to maintain intraocular pressure and to control
course of disease. It is also indicated when the rapid eye-
ball injury with visual impairment and signiﬁcant decrease
of quality of life is observed [2, 3]. The standard surgical
procedures for glaucoma treatment, like trabeculectomy,
iridectomy or deep sclerectomy are highly effective. They
are connected, however with some complications, like
intraocular infections, an excessive scar formation, perfo-
ration of anterior chamber, hypotony, choroidal detach-
ment, maculopathy and cataract [2–5]. Moreover, none of
these approaches has yet been shown to be successful
clinically in the long term.
Due to introduction of nonpenetrating procedures a
number of complications decreased and safety of patients
operated for glaucoma improved. In order to prolong the
efﬁcacy of this treatment ocular drainage intrascleral
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of ﬂuid transport in the operated eye. Such implants differ
distinctly from currently used Seton implants in their shape
and functioning. Two groups of implants are used in non-
penetrating treatment. The ﬁrst group of implants undergo
bioresorption (collagen, sodium hyaluronate-based
implants) and the second one is made of biostable poly-
mers. At present, however only one type of biostable
implants made from Poly-Megma is clinically applied,
namely T-ﬂux (Laboratory La Rochelle, France) [6–9].
Implants made of organic materials like, collagen,
hialuronate undergo biodegradation process within 6–9
months after surgery. This process may be accompanied by
an unfavourable growth of connective tissue and as a
consequence an increase of the intraocular pressure is
observed. In the postoperative phase the pressure can be
lowered by a laser procedure known as goniopuncture [9,
10]. Synthetic membrane materials based on expanded
PTFE, PP or silicone polymers may cause a chronic
inﬂammation. Moreover, their functional parameters, like
elasticity, are often not sufﬁcient for performing surgery
[11, 12]. The attempts are undertaken to produce an
intrascleral implant made of a synthetic material, which
would be well tolerated after implantation, convenient for
operative procedure and would ensure long-lasting ﬁltra-
tion of aqueous ﬂuid on an appropriate level. Increasing
demands for new and improved ophthalmic devices for
glaucoma treatment cause the necessity to elaborate new
biomaterials that could better withstand this highly speciﬁc
biological environment.
The work presents the in vivo study of the polymer
membranes designed for glaucoma treatment. The details
of the membranes preparation, their physical and
mechanical characteristics and in vitro assessment are
described elsewhere [13–15]. Our preliminary study
revealed that the elaborated membranes containing a stable
interconnected open pore system are biocompatible and
have hydrophobic surface inhibiting adsorption of aqueous
humor proteins and blockage of membrane pores [16, 17].
Such a stable porous microstructure may ensure a better
permeability for aqueous humor constituents, whereas a
hydrophobic nature of the membrane pores prevents
adhesion of peptides and proteins present in an aqueous
medium.
2 Materials and methods
2.1 Implants
The PTFE–PVDF–PP terpolymer (Aldrich Chemical Co.,
USA) and sodium alginate (Biopolymer, AS Protanal LF
20/60) were selected to prepare the samples in the form of
porous membrane. Selected terpolymer is a biostable syn-
thetic material with proved biocompability (PN-EN ISO
10993). Water soluble sodium alginate in the form of
chopped (short) ﬁbres of 200 ± 25 lm long was used as a
porogenic component. Weighted amount of ﬁbres was
mixed with the polymer solution. Subsequently, the mix-
ture was poured on a Petri dish and dried at ambient
temperature for 48 h to evaporate the solvent and the
samples in the form of thin foils were obtained. In order to
remove the porogenic phases and to create open porosity
within the polymeric material the foils were immersed in
distilled water at 80C, for 80 h. This procedure of the
material preparation allowed to obtain the samples in the
form of membrane having a high open porosity (45%) and
interconnected pore system. Porous membrane implants of
equilateral triangle shape of 3 mm side length were cut
from the foil.
2.2 Methods: plan of experiment
The non-perforating deep sclerectomy (NPDS) was per-
formed in rabbits in both eyeballs. In one eyeball deep
sclerectomy with intrascleral insertion of the implant was
performed (study group). In the same animal, on the
opposite side, only deep sclerectomy was performed,
without implant insertion (control group). The eyeball was
randomly selected to study and to control groups. The
period of clinical observation was after 14 and 30 days
from implantation. The animals were clinically evaluated
every day in order to assess wound healing and reaction to
the implant inserted. Some animals were randomly selected
and sacriﬁced after the end of clinical observation (two
groups of four animals after 14 and 30 days). Eyeballs
were removed postmortem and histopathologically evalu-
ated. Other animals have been left for further observation.
2.3 Non-perforating deep sclerectomy
with and without inserted implant: preparation
of animals for surgery
The animal experiments were performed according to the
EU ISO 10993-6 guidelines and the study protocol was
approved by the local bioethical committee (Krakow,
Poland). The same experienced surgeon performed all
operations with the same surgical procedure. The study was
performed using eight New Zealand white rabbits, age
9–12 months weighting between 3.0 and 4.0 kg. 12–18 h
before surgery the feeding was stopped, with ensured free
access to water. The intravenal access was guaranteed by
insertion cannule 20GA (Venﬂon BD 1.0) to the left
or right marginal ear vein. Before general anasthesia all
animals were subjected to intramuscular injection of
0.06 mg/kg atropine (Atropinum Sulfuricum 0.5 mg,
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123Polfa), 10 mg/kg xylazine and 3 mg/kg azaperon (Stresnil,
Janssen Animal Health BVBA). Animals were anaesthe-
tized with ketamin 5.0–15.0 mg/kg i.v. (bolus dose) with
subsequent adding maintaining dose of 1/5–1/4 of the ini-
tial dose, depending on anaesthetic effect. Immediately
before surgery two drops of 0.5% poxymetacain hyd-
rochlorate were given to conjunctival sac (Alcaine, s.a.
Alcon–Couvreue n.v.).
2.4 Non-perforating deep sclerectomy with inserted
implant (study group)
An intracorneal bridle suture was ﬁrst placed on the limbal
cornea (8-0). After pulling down the eyeball, the con-
junctiva was opened. In the area of the ciliary body, 5 mm
incision of sclera was performed, 10 mm from the limbus.
The superﬁcial square scleral ﬂap measuring 5 9 5m m
was dissected 1 mm into clear cornea. The aim of very
deep dissection of corneal ﬂap was partial exposure of
ciliary body (modiﬁcation with reference to traditional
NPDS surgery). The membrane implant of equilateral tri-
angle shape (side length: 3 mm) was inserted into the
exposed part of ciliary body. The superﬁcial scleral ﬂap
was closed with two single straight sutures (9-0). The
dissected conjunctiva was closed with a running suture. In
the control group the identical operation was performed
without the implant insertion. Postoperatively, analgesic
drugs (tramadol 1–2 mg/kg) and systemic antibiotics:
amicacin and cefuroxim (10 and 25–50 mg/kg, respec-
tively) were administered in the course of wound healing,
minimum for 7 days. Topical Tobradex (Alcaine, s.a.
Alcon–Couvreue n.v.) two guts to each conjunctival sac
was administered twice daily for 14 days.
2.5 Clinical observation
Clinical observation lasted 30 days. The primary endpoints
were the course of wound healing and disapperance of
postoperational lesions. In clinical evaluations the follow-
ing endpoints were taken into consideration: pupil reaction
to the light, light intolerance, leakage from conjunctival
sac, swelling and inﬂammation of concjunctiva, sclera
swelling and redness in wound area, postoperative scleral
adhesions, time of wound healing and clinical status of the
eyeball after 1 month observation. For evaluation of clin-
ical lesions and wound healing the modiﬁed 4-graded
scoring system (0-3) was adopted according to Hoekzem
[18] and Erkilic ¸[ 19] (Table 1).
2.6 Histopathological evaluation
Enucleated eyeballs were subjected to histopathological
procedures. As the ﬁxative 10% buffered commercially
available formaline (4% formaldehyde) was used. To pre-
pare the samples for histopathological evaluation, the
eyeball was dissected along the long axis, next to the
inserted implant, and in the case of control group—next to
the incision and suprasclerally visible sutures, through the
optic disc. The lens was subsequently removed and the
material was prepared for further laboratory procedures. It
was placed into the dehydrated containers by using
increasing methanol concentrations. Next the tissue was
placed into xylen to harden and clean the tissue. Finally,
the sample was immersed three times into liquid parafﬁn.
This stage of material preparing was realized automatically
for about 17 h. The prepared material was immersed again
with liquid parafﬁn at 60C, followed by placing it on the
specially designed frame to obtain parafﬁn block contain-
ing the sample. The embedded material was cut with
microtone. The thickness of the tissue sections was
3–4 lm. After drying of the dissected material on slides, it
was stained with hematoxylin (blue colour of nucleus) and
eosin (pink colour of cytoplasm and extracellular ele-
ments). The quantitative results were presented as mean ±
SEM. Statistical comparisons of clinical symptoms and
histopathological evaluation between the groups (study and
control) and within the groups were made with Student’s t
test, and a chosen level of signiﬁcance of P B 0.05 was
considered signiﬁcant.
Statement of Ethics We certify that all applicable insti-
tutional and governmental regulations concerning the eth-
ical use of animals were followed during this research.
3 Results
The course of wound healing and intensity of clinical
symptoms are presented in Fig. 1. Apathy of mild degree
and pain symptoms were observed in rabbits for 0–5 days
(average 2 days), loss of appetite was observed for
0-3 days (average 1 day). Immediately after surgery in
eight animals accommodation disturbancy as mydriasis and
the lack of reaction to the light were observed, lasting in
most animals 1–7 days (average 2.4) (Fig. 1a, b). In one
rabbit, the symptoms were present for 22 days, whereas in
six rabbits moderate to severe light intolerance during
1–4 days (average 1.6) was observed (Fig. 1a, b). In both
eyeballs of six other rabbits a moderate to severe sero-
purulent excharge from conjunctival sac lasting 1–4 days
(average 2.5) was observed (Fig. 1a) Immediately after
surgery in all evaluated eyeballs mild to severe swelling
and conjunctiva inﬂammation, redness and congestion of
sclera in the area of wound were observed (Fig. 1a, b, d).
Conjunctivitis lasted 1–13 days, and its duration was sta-
tistically signiﬁcant shorter in the study group (P B 0.05)
(Fig. 1 a, b, d). After 14 days, the symptoms of
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123inﬂammation and swelling of conjunctiva were no longer
present in any animal (Fig. 1d). Swelling and redness of
sclera in the area of wound lasted on average 3–20 days
(9.5 ± 3.6 and 9.0 ± 4.2 in the study group and control
group, respectively) (Fig. 1a, b). In both groups swelling
and redness in the area of scleral wound signiﬁcantly
decreased. However, in 13 eyeballs from the study group
and 14 from control group a mild to moderate swelling and
redness were still present (Fig. 1b). Difference between the
groups was not statistically signiﬁcant. After 1 month
observation in six eyeballs in study group and seven in
control group a mild to moderate redness was still present,
without features of swelling. In all eyeballs of the study
group scleral congestion in the area of the wound was
observed, while in 15 eyeballs of the control group it was
still present 14 days after surgery. At the same time in both
groups a statistically signiﬁcant decrease in congestion
from severe to moderate and mild was observed. Differ-
ence between both groups was not statistically signiﬁcant.
After 1 month, in 16/18 eyeballs in the study group and in
14/18 eyeballs in the control group a mild to moderate
congestion was still present. No difference in the degree of
congestion between the groups was observed. In both
groups mild to severe adhesions in wound area were
present on average 4.5 (3–7) days after surgery (Fig. 1a, b).
In both groups adhesions were found in 20 evaluated
eyeballs. After 14 days, adhesions were still present in 18
and 16 eyeballs in the study group and the control group,
respectively (Fig. 1c). Their intensity did not signiﬁcantly
change, while difference between the group was
Table 1 Modiﬁed scale of
clinical lesions according to
Hoekzem [17] and Erkilic ¸[ 18]
Clinical signs Duration time Grade
Grade Score
Mydriasis, without
reaction to light
Days Not evaluated Not evaluated
Photophobia Days No 0
Mild 1
Moderate 2
Severe 3
Leakage from conjunctival sac Days No 0
Mild 1
Moderate 2
Severe 3
Swelling and inﬂammation
of concjunctiva
Days No 0
Mild 1
Moderate 2
Severe 3
Sclera swelling and
redness in wound area
Days No 0
Mild 1
Moderate 2
Severe 3
Scleral hyperemia in
wound area
From the day after operation No 0
Mild 1
Moderate 2
Severe 3
Adhesion From the day after operation No 0
Mild 1
Moderate 2
Severe 3
Scar From the day after operation No 0
Mild 1
Moderate 2
Severe 3
Minimum 0
Maximum 21
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123statistically signiﬁcant. One month after surgery adhesions
in both groups were still present in 12/18 of the evaluated
eyeballs in each group, without statistically signiﬁcant
difference between groups, Fig. 1d. Between 14 and
30 days the size and extent of adhesions did not decrease
signiﬁcantly. In both groups wound cicatrisation process
was observed on average from the day 5 (5–11). The
observed cicatrization process was from a mild to moderate
degree, and only in two eyeballs within the study group the
stage three of cicatrization was present. After 14 days from
surgery in 12 eyeballs in the study group and in eight
eyeballs in control group small scars were noticed
(Fig. 1c). There was no signiﬁcant decrease of scar size.
Differences between groups were not statistically signiﬁ-
cant. One month after surgery small scars were still present
in six eyeballs in study group and four in control group. In
both groups a signiﬁcant decrease of scar size was
observed between days 14 and 30 after surgery. There was
no a signiﬁcant difference between the groups (Fig. 1d).
One month after surgery postoperative side effects, like
congestion and/or scar and/or adhesion were still present in
11 eyeballs in the study group and 10 eyeballs in the
control group. From the whole group consisting of 18
animals, on the last day (30 day) lesions were more evident
in the eyeballs with the implants in seven animals and in
ﬁve animals without implants. In six animals lesions after
surgery in both eyeballs were comparable or they were not
noticed at all.
Results of histopathological evaluation of removed
eyeballs are gathered in Table 2 and Fig. 2. On histopa-
thological evaluation, an increase of amount of resorption
granulation was the only reaction observed around the
implant, deﬁned as not matured connective tissue, which is
always present in case of tissue destruction. Multinucleated
histocytes, phagocyting, removing altered tissue and for-
eign bodies are typical features of this tissue. After
Fig. 1 Clinical observations: a Duration of clinical symptoms during
30-day observation; group C control group (eyeballs without
implant), group I study group (eyeballs with inserted implant);
b Maximum of intensity of clinical symptoms and the course of
wound healing after 30-day observation; a statistical difference SD
between groups P B 0.05, b SD between days 1 and 14 in study group
P B 0.05, c SD between days 1 and 14 in control P B 0.05;
c Intensity of clinical symptoms and the course of wound healing after
14 days of observation; a SD between groups I/C P B 0.05, b SD
between days 1 and 14 in study group P B 0.05, c SD between days 1
and 14 in control group P B 0.05, d SD between days 14 and 30 in
study group P B 0.05; d Intensity of clinical symptoms and the
course of wound healing after 30 days of observation; a SD between
groups P B 0.05, b SD between days 1 and 14 in study group
P B 0.05, c SD between days 1 and 14 in control P B 0.05, d SD
between days 14 and 30 in study group P B 0.05
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12314 days, a moderate amount of granulation was observed in
one eyeball, and after 30 days a high amount of granulation
was present in three eyeballs. The observed difference
inside the sclera related to both times of observation was
statistically signiﬁcant, at P B 0.05 (Table 2). In spite of
scleral dissection with chronic inﬂammatory, inﬂammation
could also be seen. In eyeballs with the inserted implants
only granulation was present. After follow up of 14 days in
one eyeball a high amount of granulation tissue was found.
In one eyeball of the control group after 14 days a high
amount of granulation tissue was present, and after 30 days
a moderate amount of granulation in two eyeballs was
noticed. In the ciliary body there was a high amount of
granulation in one eyeball with the implant and a small
amount of granulation in the other one after 14 and
30 days, respectively. Moreover, in one eyeball a moderate
inﬂammation on days 14 and 30 was observed. In control
only a mild to moderate stromal oedema was observed in
the ciliary body, without any features of histopathological
lesions. The difference between both groups was
statistically signiﬁcant (Table 2). In the group with the
implants, 14 days after surgery a small amount of granular
tissue was observed subconjunctivally in two eyeballs; in
some eyeballs a mild inﬂammation with focal sclerosis and
hyalinization was observed in this area. In control group
focal ﬁbrosis and hyalinization of a moderate degree was
observed subconjunctivally in one eyeball. After 1 month,
no subconjunctival changes were found on histopatholo-
gical evaluation in any of the analyzed groups. Addition-
ally, in few eyeballs moderate or severe haemorrhages
were noticed on day 14 in study and control group. A mild
and moderate ﬁbrosis was found in two eyeballs in control
group. After 1 month, an abundant connective tissue and
moderate number of thin-walled vessels created in both
groups; additionally, in one eyeball of the study group
small single haemorrhages and congestion were observed.
On days 14 and 30, in one eyeball in control group a
purulent inﬂammatory inﬁltration, consisting mainly of
granulocytes, was found. No purulent inﬁltration was
observed in group with the implant.
Table 2 The histopathological evaluation
Changes in histopathological evaluation Day 14 Day 30
I( n = 4) C (n = 4) I (n = 4) C (n = 4)
Average Range Average Range Average Range Average Range
Implant
Resorption granulation tissue around implant 0.50
a 0.00-2.00 – – 2.25
a 0.00-3.00 – –
Chronic inﬂammatory inﬁltration around implant 0.00 0.00 – – 0.75 0.00-3.00 – –
Sclera
Resorption granulation tissue in sclera 0.75 0.00-3.00 0.75 0.00-3.00 0.00 0.00 0.00 0.00-2.00
Scleral dissection 0.00 0.00 0.75 0.00-3.00 0.00 0.00 0.00 0.00
Inﬂammatory inﬁltration 0.00 0.00 0.25 0.00-1.00 0.00 0.00 0.00 0.00
Sutures
Resorption granulation tissue 1.00 0.00-2.00 0.75 0.0-3.00 0.75 0.00-3.00 0.00 0.00
Ciliary body
Resorption granulation tissue 0.75 0.00-3.00 0.00 0.00 0.25 0.00-1.00 0.00 0.00
Chronic inﬂammation 0.50 0.00-2.00 0.00 0.00 0.50 0.00-2.00 0.00 0.00
Stromal oedema 0.00 0.00 0.00
a 0.00 0.50 0.00-2.00 1.25
a 0.00-2.00
Subconjunctival lesions
Granulation tissue 0.75 0.00-2.00 0.00 0.00 0.00 0.00 0.00 0.00
Haemorrhages 0.25 0.00-1.00 0.00 0.00 0.00 0.00 0.00 0.00
Fibrosis 0.50 0.00-2.00 0.00 0.00 0.50 0.00-2.00 0.00 0.00
Hyalinization 0.50 0.00-2.00 0.00 0.00 0.50 0.00-2.00 0.00 0.00
Whole eyeball
Haemorrhages 0.50 0.00-2.00 0.75 0.00-3.00 0.25 0.00-1.00 0.00 0.00
Capillary proliferation 0.00 0.00 0.00 0.00 0.75 0.00-3.00 0.50 0.00-2.00
Congestion 0.00 0.00 0.00 0.00 0.50 0.00–1.00 0.00 0.00
Purulent inﬁltration 0.00 0.00 0.75 0.00-3.00 0.00 0.00 0.50 0.00-2.00
a Signiﬁcant difference at P B 0.05 The evaluation scale of histological signs in the range from 0 to 3 points. 0 no signs, 1 mild, 2 moderate, 3
severe, I implant, C control
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1234 Discussion
The purpose of this study was to assess on animal model a
new biomaterial for glaucoma treatment. This biomaterial
was used for manufacturing implants applied in glaucoma
treatment by a non-perforating deep sclerectomy method.
The biomaterial was manufactured in the form of a poly-
meric membrane containing a system of canalicular open
pores (open porosity about 50%) enabling free intraocular
ﬂuid circulation. The membrane allows to keep the intra-
ocular pressure on a physiological level. In our previous
studies, the optimal porous interconnected canalicular
microstructure aimed at leveling the pressure gradient was
determined [23]. The elaborated material has a suitable
biomechanical durability and is resistant to long-lasting
static and dynamic loading. Additional advantage of the
material are its physicochemical surface properties, meet-
ing the requirements for ophtalmological implants, namely
hydrophobicity and low surface energy that hinder block-
ing of membrane pores [24].
In the previous study the in vitro biocompatibility of this
material was proved on mouse ﬁbroblast cell line 3T3/Balb
using a direct contact method [24]. Degradation studies
performed according to the EN-PN ISO 10993-12 standard
conﬁrmed stability and inertness of composite membrane
in vitro conditions.
The ﬁrst part of the study performed on rabbit model
was realized to verify and conﬁrm the results of in vitro
study and to determine the animal eyeball reaction to the
inserted implants. Observations in the course of wound
healing and histopathological changes in relatively short
time (1 month) were made. In this time some clinical
symptoms indicating that the course and the reactions
intensity seem to be typical for wound healing process. On
the ﬁrst day after surgery moderate to severe conjunctivitis
with oedema and discharge from the conjunctival sac are
the main observed clinical symptom. The main factor
responsible for severe inﬂammation of the conjunctival sac
mucous membrane is its mechanical irritation during sur-
gery. Statistically signiﬁcant difference (P B 0.05) in
duration time of conjunctivitis was observed between the
study and control groups favoring the study group. In some
rabbits immediately after surgery mydriasis with photo-
phobia was observed. It seems, however, that these
symptoms were not eyeball reaction to inserted implant,
since the duration and intensity of symptoms in both
groups were identical (P = 1.00). In evaluation of wound
healing and tissue reaction to implant the symptoms
relating to the site of implant insertion are extremely
important. They include redness, oedema and congestion of
sclera in wound area as well as adhesions and scar devel-
oped during healing. Immediately after surgery a severe
Fig. 2 Histopathological
evaluation of removed eyeballs:
a 14th day without implant—
congestion of sclera, with focal
areas of resorption granular
tissue, formed in nodules,
localized around surgical suture;
b 14th day with implant: the
implant in central part
surrounded by an abundant
granular tissue; c 1 month
without implant—abundant
granular tissue; d 1 month with
implant—the implant visible in
the central part surrounded by
unspeciﬁc partially resorption
granular tissue, resorption
granular tissue can be seen also
sub conjunctivally, oedema of
cillary body
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123scleral congestion in wound area with a moderate to severe
redness and oedema of similar intensity were observed in
both groups. On consecutive healing days adhesion and
scar were present. Difference between groups was
observed for adhesion only, and intensity of other symp-
toms was similar in both groups. In both groups (study and
control), the course of wound healing was very similar
accompanied by resolution of redness and scleral oedema.
After 1 month observation of scleral wound area, conges-
tion adhesion and scar formation had similar intensity in
both groups. During the ﬁrst month the course of wound
healing was similar in both groups. In the eyeballs group
with the implants neither symptoms of intolerance nor
implant rejection were observed. Histopathological study
revealed, however that there were many changes observed
in different anatomical parts of eyeball. In the proximity of
the implant site resorption of granular tissue and a mild
inﬂammation were observed. It is typical for healing pro-
cess with the feature of foreign body reaction. It is
important that a similar granular reaction was found in the
area of sutures in both groups. Numerous histopathological
lesions in area of sclera, ciliary body, conjunctiva or entire
eyeball were very mild with no statistically signiﬁcant
difference between the groups. No lesions typical for
implant intoleration were found on histopahological eval-
uation. It is worth noticing, however that no purulent
inﬂammation was observed in the study group, contrary to
that of purulent inﬂammation observed in control. Similar
studies performed with the use of different type of implants
showed analogous course of healing and similar histopa-
thological changes. The crucial period in wound healing
after implant insertion were the ﬁrst 2 weeks after surgery.
It was conﬁrmed in similar studies of implants made of
silicone material [18, 20], catgut, nylon [18], zirconium
[21], natrium hyaluronate [20], collagen [22, 23] and its
derivates Bio-1, Bio-2, Bio-3 [6], as well as synthetic
polymers and copolymers e.g. HEMA, HEMA-co-MMA
[4], e-PTFE [7] or SIBS [9]. The most pronounced clinical
symptoms were observed on the ﬁrst 4–5 days after sur-
gery. Mild clinical symptoms were observed 14 days after
surgery, and some of them were still present after 30 days.
Only in studies evaluating implants made of catgut and its
polymers mild clinical symptoms were observed 1 month
after surgery [22, 23]. They include proliferation of capil-
laries in sclera, inﬂammatory inﬁltration around implant
[18, 20–22, 24, 25], proliferation of connective tissue
around implant [20, 26], granular reaction [18, 20, 24],
ﬁbrosis [18, 20], inﬂammation around sutures [18, 23]. As
it results from available literature the lesion sites increase
within the period of 14–30 days after surgery, what may be
associated with a natural healing process and tissue
reconstruction after surgery.
5 Conclusions
While the in vivo study of the terpolymer-based biomate-
rial will be continued, the following conclusions can be
reached at present:
Clinical symptoms of a moderate degree were observed,
and histopathological changes were typical for a foreign
body implantation. At the end of the in vivo study (after
30 day implantation) no signiﬁcant difference was noted
between the study and control groups. Moreover, similar-
ities observed in both groups and relatively mild histopa-
thological changes in tissue surrounding the inserted
implants indicate that symptoms observed in the in vivo
rabbit model may come from deep scleral trauma caused by
surgery, and not by the presence of the implant itself.
Data obtained from previous in vitro study, in con-
junction with the in vivo evaluation of the terpolymer-
based implant are pertinent to the planned biomedical use
[15, 17]. There is reasonable requirement of continuation
of preclinical studies and evaluation of implant during
longer period of observation. It must however be reserved
that the reaction and toleration of biomaterial used in this
study may differ in human and other mammal species.
Positive evaluation of terpolymer-based implant mate-
rial may provide a rationale to use it into clinical studies in
eyeball surgery.
Acknowledgements The study was supported by Ministry of Sci-
ence and Higher Education, Grant No N 518 028 32/1769. Ewa
Stodolak is beneﬁciary of The Foundation for Polish Science (FNP) in
Domestic Grants for Young Scientists Program.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Eldaly M, Anand N, Bunce C,Khafagy M. Non-penetrating ﬁl-
tration surgery versus trabeculectomy for open angle glaucoma.
(Protocol) Cochrane Database Syst Rev. 2008; Issue 2.
CD007059. DOI:10.1002/14651858.CD007059.
2. Burr JM, Mowatt G, Herna ´ndez R, Siddiqui MAR, Cook J,
Lourenco T, et al. The clinical effectiveness and cost-effective-
ness of screening for open angle glaucoma: a systematic review
and economic evaluation. Health Technol Assess. 2007;11(41):
1–206.
3. Khaw PT, Shah P, Elkington AR. Glaucoma—2: treatment. BMJ.
2004;328(7432):156–8.
4. King A, Migdal C. Clinical management of glaucoma. J R Soc
Med. 2000;93(4):175–7.
5. Dada T, Aggarwal A, Minudath KB, Vanathi M, Choudhary S,
Gupta V, Sihota R, Panda A. Post-penetrating keratoplasty
glaucoma. Indian J Ophthalmol. 2008;56(4):269–77.
2850 J Mater Sci: Mater Med (2010) 21:2843–2851
1236. Mandal AK. Current concepts in the diagnosis and management
of developmental glaucomas. Indian J Ophthalmol. 1993;41:
51–70.
7. Schwartz KS, Lee RK, Gedde SJ. Glaucoma drainage implants: a
critical comparison of types. Curr Opin Ophthalmol. 2006;17(2):
181–9.
8. Ishida K, Mandal AK, Netland PA. Glaucoma drainage implants
in pediatric patients. Ophthalmol Clin North Am. 2005;18(3):
431–42.
9. Chiou AGY, Mermoud A, Underdahl JP, Schnydrer CC. An
ultrasound biomicroscopic study of eyeballs after deep sclerec-
tomy with collagen implant. Ophthalmology. 1998;105:746–50.
10. Klinge U, Klosterhalfen B, Ottinger AP, Junge K. PVDF as a new
polymer for the construction of surgical meshes. Biomaterials.
2002;23:3487–93.
11. Chunseng F, Baoli S, Guomin L, Yonglie W. Preparation and
properties of microporous membrane from poly(vinylidene ﬂuo-
ride-co- tetraﬂuoethylene) for membrane distillation. J Memb Sci.
2004;237:15–24.
12. Shaarawy T, Nguyen Cr, Achache F. Comparative study between
deep scleretomy with and without collagen implant: long term
follow-up. Br J Ophthalmol. 2004;88(1):95–8.
13. Stodolak E, Czajkowska B, Blazewicz M, Mikolajczyk T, Wol-
owska-Czapnik D. In vitro behavior of PP-PVDF-PTFE ter-
polymer modiﬁed with alginate ﬁbres. Eng Biomater. 2004;
38–42:208–11.
14. Zaczynska E, Czarny A, Zywicka B, Stodolak E, Blazewicz M.
The study of cytotoxity of ﬁbrous composite materials. Eng
Biomater. 2006;54–55:15–8.
15. Stodolak E, Wieczorek J, Gumula T, Blazewicz S, Leszczynski
R. The new generation of composite membranes for ophthal-
mology application. In: 17th International conference on com-
posite materials. July 27–31, 2009, Edinburgh, UK.
16. Stodolak E, Krok M, Gumula T, Blazewicz S. Composite mem-
branes materials for ophthalmological implants. Composites.
2009;4:352–7.
17. Stodolak E, Zaczynska E, Blazewicz M, Wolowska-Czapnik D,
Leszczynski R. Membrane composite materials for medical
application. Primary material and biological study. Composites.
2006;4:47–51.
18. Hoekzema R, Murray PI, van Haren MA, Helle M, Kijlstra A.
Analysis of interleukin-6 in endotoxin-induced uveitis. Invest
Ophthalmol Vis Sci. 1991;32:88–95.
19. Erkilic ¸ K, Ozkiris ¸ A, Evereklioglu C, Kontas ¸O ,G u ¨ler K, Dogan
H. Deep sclerectomy with various implants: an experimental and
histopathologic study in a rabbit model. Ophthalmologica.
2004;218:264–9.
20. Kaluzny JJ, Jozwicki W, Wisniewska H. Histological biocom-
patibility of new, non-absorbable glaucoma deep sclerectomy
implant. J Biomed Mater Res B. 2007;81(2):403–9.
21. Basso A, Roy S, Mermoud A. Biocompatibility of an x-shaped
zirconium implant in deep sclerectomy in rabbits. Graefes Arch
Clin Exp Ophthalmol. 2008;246(6):849–55.
22. Ro ¨nkko ¨ S, Rekonen P, Sihvola R, Kaarniranta K, Puustja ¨rvi T,
Tera ¨svirta M, Uusitalo H. Histopathology of the three implanted
degradable biopolymers in rabbit eyeball. J Biomed Mater Res A.
2009;88(3):717–24.
23. Nguyen C, Boldea RC, Roy S, Shaarawy T, Uffer S, Mermoud A.
Outﬂow mechanisms after deep sclerectomy with two different
designs of collagen implant in an animal model. Graefes Arch
Clin Exp Ophthalmol. 2006;244(12):1659–67.
24. Jallet V, Gautier SE, Parel JM, Matsui T, Haeﬂiger I, Kondo H,
Kato H, Savoldelli M, Pouliquen Y. Novel synthetic meshwork
for glaucoma treatment. I. Design and preliminary in vitro and
in vivo evaluation of various expanded poly(tetraﬂuoroethylene)
materials. J Biomed Mater Res. 1999;47(2):260–9.
25. Acosta AC, Espana EM, Yamamoto H, Davis S, Pinchuk L,
Weber BA, Orozco M, Dubovy S, Fantes F, Parel JM. A newly
designed glaucoma drainage implant made of poly(styrene-b-
isobutylene-b-styrene): biocompatibility and function in normal
rabbit eyeballs. Arch Ophthalmol. 2006;124(12):1742–9.
26. Kivalo M, Siren V, Raitta C, Immonen I. Biodegradable tube
implants in experimental glaucoma surgery in the rabbit. J Mater
Sci Mater Med. 1999;10(1):53–8.
J Mater Sci: Mater Med (2010) 21:2843–2851 2851
123